Day One Biopharmaceuticals (DAWN) Stock Forecast & Price Target

Compare

374 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

DAWN Analyst Ratings

Strong Buy

7 Buy

1 Hold

0 Sell

Based on 8 analysts giving stock ratings to

Day

One Biopharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

DAWN Stock 12 Month Forecast

Average Price Target

$25.40

▲(177.90% Upside)

Based on 8 Wall Street analysts offering 12 month price targets for Day One Biopharmaceuticals in the last 3 months. The average price target is $25.40 with a high forecast of $34.00 and a low forecast of $16.00. The average price target represents a 177.90% change from the last price of $9.14.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","20":"$20","35":"$35","12.5":"$12.5","27.5":"$27.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":34,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$34.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$25.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$16.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,12.5,20,27.5,35],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.44,9.483076923076924,11.526153846153846,13.56923076923077,15.612307692307692,17.655384615384616,19.69846153846154,21.74153846153846,23.784615384615385,25.82769230769231,27.87076923076923,29.913846153846155,31.95692307692308,{"y":34,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.44,8.821538461538461,10.203076923076923,11.584615384615384,12.966153846153846,14.347692307692308,15.729230769230767,17.11076923076923,18.49230769230769,19.873846153846152,21.255384615384614,22.636923076923075,24.018461538461537,{"y":25.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.44,8.098461538461539,8.756923076923076,9.415384615384616,10.073846153846153,10.732307692307693,11.39076923076923,12.049230769230768,12.707692307692307,13.366153846153846,14.024615384615384,14.683076923076921,15.341538461538459,{"y":16,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":14.65,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.84,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.67,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.37,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.06,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.61,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.62,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.01,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.61,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.65,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.4,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.88,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.44,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$34.00

Average Price Target$25.40

Lowest Price Target$16.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Ami Fadia

Needham

$16

Buy

75.05%

Upside

Reiterated

11/05/25

Positive Outlook for Day One Biopharmaceuticals: Strong Q3 Performance and Upgraded Guidance Justify Buy Rating

Kelsey Goodwin

Piper Sandler

$25→$26

Buy

184.46%

Upside

Reiterated

11/05/25

Day One Biopharmaceuticals price target raised to $26 from $25 at Piper SandlerDay One Biopharmaceuticals price target raised to $26 from $25 at Piper Sandler

Andres Y. Maldonado

H.C. Wainwright

$25

Buy

173.52%

Upside

Reiterated

11/05/25

H.C. Wainwright Sticks to Their Buy Rating for Day One Biopharmaceuticals (DAWN)Hence, we reiterate our Buy rating and $25 price target.

Alec Stranahan

Bank of America Securities

―

Buy

―

Reiterated

11/05/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: PROCEPT BioRobotics (NASDAQ: PRCT), Day One Biopharmaceuticals (NASDAQ: DAWN) and Exelixis (NASDAQ: EXEL)

Soumit Roy

JonesTrading

$26

Buy

184.46%

Upside

Reiterated

11/05/25

Strong Buy Recommendation for Day One Biopharmaceuticals Driven by Robust Financial Performance and Promising Drug EfficacyWe expect in subsequent quarters that physician hesitancy to adopting Ojemda will continue to thaw, especially in the harder-to-penetrate priority 3 group. We see the upcoming 3-year readout from the Phase 2 FIREFLY-1 trial as important, as the management stated it will help answer a key provider question, "what happens after you give patients 24 months of therapy [Ojemda] once they come off treatment?".

Tara Bancroft

TD Cowen

$34

Buy

271.99%

Upside

Reiterated

11/04/25

Analysts Offer Insights on Healthcare Companies: Day One Biopharmaceuticals (NASDAQ: DAWN) and Sandoz Group Ltd (Other OTC: SDZXF)

Matthew Biegler

Oppenheimer

―

Hold

―

Reiterated

11/04/25

Analysts Offer Insights on Healthcare Companies: Taysha Gene Therapies (NASDAQ: TSHA) and Day One Biopharmaceuticals (NASDAQ: DAWN)

Anupam Rama

J.P. Morgan

―

Buy

―

Reiterated

08/11/25

Promising Growth and Stability Drive Buy Rating for Day One Biopharmaceuticals

Robert Driscoll

Wedbush

$25

Buy

173.52%

Upside

Reiterated

08/05/25

Andrea Tan

Goldman Sachs

$18

Buy

96.94%

Upside

Reiterated

07/15/25

Day One Biopharmaceuticals (DAWN) Gets a Buy from Goldman Sachs

Joseph Catanzaro

Mizuho Securities

$40

Buy

337.64%

Upside

Reiterated

02/26/25

Piper Sandler Sticks to Its Buy Rating for Day One Biopharmaceuticals (DAWN)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Ami Fadia

Needham

$16

Buy

75.05%

Upside

Reiterated

11/05/25

Positive Outlook for Day One Biopharmaceuticals: Strong Q3 Performance and Upgraded Guidance Justify Buy Rating

Kelsey Goodwin

Piper Sandler

$25→$26

Buy

184.46%

Upside

Reiterated

11/05/25

Day One Biopharmaceuticals price target raised to $26 from $25 at Piper SandlerDay One Biopharmaceuticals price target raised to $26 from $25 at Piper Sandler

Andres Y. Maldonado

H.C. Wainwright

$25

Buy

173.52%

Upside

Reiterated

11/05/25

H.C. Wainwright Sticks to Their Buy Rating for Day One Biopharmaceuticals (DAWN)Hence, we reiterate our Buy rating and $25 price target.

Alec Stranahan

Bank of America Securities

―

Buy

―

Reiterated

11/05/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: PROCEPT BioRobotics (NASDAQ: PRCT), Day One Biopharmaceuticals (NASDAQ: DAWN) and Exelixis (NASDAQ: EXEL)

Soumit Roy

JonesTrading

$26

Buy

184.46%

Upside

Reiterated

11/05/25

Tara Bancroft

TD Cowen

$34

Buy

271.99%

Upside

Reiterated

11/04/25

Analysts Offer Insights on Healthcare Companies: Day One Biopharmaceuticals (NASDAQ: DAWN) and Sandoz Group Ltd (Other OTC: SDZXF)

Matthew Biegler

Oppenheimer

―

Hold

―

Reiterated

11/04/25

Analysts Offer Insights on Healthcare Companies: Taysha Gene Therapies (NASDAQ: TSHA) and Day One Biopharmaceuticals (NASDAQ: DAWN)

Anupam Rama

J.P. Morgan

―

Buy

―

Reiterated

08/11/25

Promising Growth and Stability Drive Buy Rating for Day One Biopharmaceuticals

Robert Driscoll

Wedbush

$25

Buy

173.52%

Upside

Reiterated

08/05/25

Andrea Tan

Goldman Sachs

$18

Buy

96.94%

Upside

Reiterated

07/15/25

Day One Biopharmaceuticals (DAWN) Gets a Buy from Goldman Sachs

Joseph Catanzaro

Mizuho Securities

$40

Buy

337.64%

Upside

Reiterated

02/26/25

Piper Sandler Sticks to Its Buy Rating for Day One Biopharmaceuticals (DAWN)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Day One Biopharmaceuticals

1 Month

xxx

Success Rate

9/16 ratings generated profit

Average Return

+3.39%

reiterated a xxx

rating 2 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 56.25% of your transactions generating a profit, with an average return of +3.39% per trade.

3 Months

xxx

Success Rate

6/14 ratings generated profit

Average Return

-5.64%

reiterated a xxx

rating 8 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 42.86% of your transactions generating a profit, with an average return of -5.64% per trade.

1 Year

Alec StranahanBank of America Securities

Success Rate

8/16 ratings generated profit

Average Return

-13.15%

reiterated a buy rating 2 days ago

Copying Alec Stranahan's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -13.15% per trade.

2 Years

xxx

Success Rate

7/16 ratings generated profit

Average Return

-14.04%

reiterated a xxx

rating 2 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 43.75% of your transactions generating a profit, with an average return of -14.04% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

DAWN Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, DAWN has received 9 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. DAWN average Analyst price target in the past 3 months is 25.40.

Each month's total comprises the sum of three months' worth of ratings.

DAWN Financial Forecast

DAWN Earnings Forecast

Next quarter’s earnings estimate for DAWN is -$0.21 with a range of -$0.36 to -$0.16. The previous quarter’s EPS was -$0.19. DAWN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year DAWN has Preformed in-line its overall industry.

DAWN Sales Forecast

Next quarter’s sales forecast for DAWN is $43.60M with a range of $37.54M to $46.74M. The previous quarter’s sales results were $39.80M. DAWN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year DAWN has Preformed in-line its overall industry.

DAWN Stock Forecast FAQ

What is DAWN’s average 12-month price target, according to analysts?

Based on analyst ratings, Day One Biopharmaceuticals’s 12-month average price target is 25.40.

What is DAWN’s upside potential, based on the analysts’ average price target?

Day One Biopharmaceuticals has 177.90% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is DAWN a Buy, Sell or Hold?

Day One Biopharmaceuticals has a consensus rating of Strong Buy which is based on 7 buy ratings, 1 hold ratings and 0 sell ratings.

What is Day One Biopharmaceuticals’s price target?

The average price target for Day One Biopharmaceuticals is 25.40. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $34.00 ,the lowest forecast is $16.00. The average price target represents 177.90% Increase from the current price of $9.14.

What do analysts say about Day One Biopharmaceuticals?

Day One Biopharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of DAWN?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Day One Biopharmaceuticals (DAWN) Stock Forecast & Price Target

DAWN Analyst Ratings

DAWN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Day One Biopharmaceuticals

DAWN Analyst Recommendation Trends

DAWN Financial Forecast

DAWN Earnings Forecast

DAWN Sales Forecast

DAWN Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts